Developing an industrial artemisinic acid fermentation process to support the cost‐effective production of antimalarial artemisinin‐based combination therapies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Artemisinin‐based combination therapies (ACTs) are currently unaffordable for many of the people who need them most. A major cost component of ACTs is the plant‐derived artemisinin. A fermentation process for a precursor to artemisinin might provide a viable second source to stabilize the artemisinin supply and therefore reduce price. The heterologous production of artemisinic acid, an artemisinin precursor, by Saccharomyces cerevisiae was improved 25‐fold from a 100 mg/L flask process to a 2.5 g/L process in bioreactors. A defined medium fed‐batch process with galactose as the carbon source and inducer was developed, with titers of 1.3 g/L. In this strain ERG9 was controlled with promoter Pmet3 so that methionine repressed the sterol biosynthesis pathway and increased precursor availability for artemisinic acid biosynthesis. Addition of methionine to the process increased artemisinic acid titers to 1.8 g/L. A dissolved oxygen‐stat algorithm was developed, which simultaneously controlled the agitation and feed pump. This improved process control and increased titers to 2.5 g/L.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., et al. (2006) · Nature · doi:10.1038/nature04640 · Cited by 2,805 · cited 7×
“Production in SD medium was somewhat lower than previously reported (100 mg/L).(4) Production in bioreactor batch medium was more than double the production in SD medium primarily due to better cell growth in bioreactor batch medium (9.”
BackgroundMethodInfluentialNewman, J. D., Marshall, J., Chang, M., Nowroozi, F., Paradise, E., Pitera, D., Newman, K. L., & Keasling, J. D. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21017 · Cited by 257
Source of New Hope Against Malaria is in Short Supply
Enserink, M. (2005) · Science · doi:10.1126/science.307.5706.33 · Cited by 85
Production of the artemisinin precursor amorpha-4,11-diene by engineered Saccharomyces cerevisiae
Lindahl, A.-L., Olsson, M. E., Mercke, P., Tollbom, Ö., Schelin, J., Brodelius, M., & Brodelius, P. E. (2006) · Biotechnology Letters · doi:10.1007/s10529-006-0015-6 · Cited by 82 · cited 1×
“cerevisiae.(12,13) Production of artemisinic acid in S.”
Cited by
Westfall, P. J., Pitera, D. J., Lenihan, J. R., Eng, D., Woolard, F. X., Regentin, R., Horning, T., Tsuruta, H., Melis, D. J., Owens, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110740109 · Cited by 722
Self-citationPan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., et al. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/627375 · Cited by 687
Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development
Paddon, C. J., & Keasling, J. D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3240 · Cited by 675
Tsuruta, H., Paddon, C. J., Eng, D., Lenihan, J. R., Horning, T., Anthony, L. C., Regentin, R., Keasling, J. D., Renninger, N. S., & Newman, J. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004489 · Cited by 363
Self-citationMethylerythritol Phosphate Pathway of Isoprenoid Biosynthesis
Zhao, L., Chang, W.-C., Xiao, Y., Liu, H.-W., & Liu, P. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052010-100934 · Cited by 353
The potential of the mevalonate pathway for enhanced isoprenoid production
Liao, P., Hemmerlin, A., Bach, T. J., & Chye, M.-L. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.03.005 · Cited by 332
Becker, J., & Wittmann, C. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201409033 · Cited by 297
Triterpenoid biosynthesis and engineering in plants.
Sawai, S., & Saito, K. (2011) · Frontiers in Plant Science · doi:10.3389/fpls.2011.00025 · Cited by 272
Industrial biotechnology—the future of green chemistry?
Wenda, S., Illner, S., Mell, A., & Kragl, U. (2011) · Green Chemistry · doi:10.1039/c1gc15579b · Cited by 238
Metabolic engineering of Saccharomyces cerevisiae for production of ginsenosides
Dai, Z., Liu, Y., Zhang, X., Shi, M., Wang, B., Wang, D., Huang, L., & Zhang, X. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2013.10.004 · Cited by 236
Metabolic engineering of microorganisms for the synthesis of plant natural products
Marienhagen, J., & Bott, M. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.06.001 · Cited by 224
Zhuang, Y., Yang, G.-Y., Chen, X., Liu, Q., Zhang, X., Deng, Z., & Feng, Y. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.04.009 · Cited by 170
“The media for seed and batch fermentation were modified from previously described media (Lenihan et al., 2008), and 5g/L of lysine was added.”
MethodGenetic engineering of artemisinin biosynthesis: prospects to improve its production
Abdin, M. Z., & Alam, P. (2015) · Acta Physiologiae Plantarum · doi:10.1007/s11738-015-1771-5 · Cited by 25
“The integration and overexpression of these genes in the recombinant yeast led to the production of 2.5 g/L artemisinic acid in the galactose-based fermentation process (Lenihan et al. 2008).”
BackgroundInfluential
Metadata
- Authors
- Lenihan, J. R., Tsuruta, H., Diola, D., Renninger, N. S., & Regentin, R.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2008-09
- Volume
- 24
- Issue
- 5
- Pages
- 1026-1032
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2086031250
- Cited by
- 85
- References
- 4
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.